Zyceva 150mg Tablet contains Erlotinib, a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. By selectively inhibiting the EGFR tyrosine kinase, Erlotinib interferes with the signaling pathways involved in tumor cell proliferation and survival, thereby slowing disease progression. Zyceva is indicated for patients with locally advanced or metastatic NSCLC with activating EGFR mutations and for use in combination with gemcitabine in locally advanced, unresectable, or metastatic pancreatic cancer. The recommended dosage is 150mg once daily, taken orally on an empty stomach to optimize absorption. Common adverse effects include rash, diarrhea, anorexia, and fatigue, which are generally manageable with supportive care. Serious adverse reactions may include interstitial lung disease and hepatotoxicity, necessitating close monitoring during therapy. Patients should be advised to report any new or worsening respiratory symptoms promptly. Zyceva should be used with caution in patients with hepatic impairment or pre-existing pulmonary conditions. Drug interactions may occur with CYP3A4 inducers or inhibitors, requiring dose adjustments or alternative therapies. Zyceva 150mg Tablet offers a targeted therapeutic option for patients with specific EGFR mutation-positive cancers, contributing to improved clinical outcomes.